Polymeric whey protein encapsulated antioxidant compounds and methods of making same
Through polymerized whey protein encapsulation technology, the problem of low absorption and utilization efficiency of glutathione and 3,3'-diindole methane in the body is solved, and higher bioavailability and stability are achieved, which improves its Antioxidant activity and pharmacokinetic kinetics.
Patent Information
- Application Number
- CN202411102245.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-08-18
- Filing Date
- 2021-08-17
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-08-17
AI Technical Summary
The prior art is difficult to improve the bioavailability and stability of glutathione and 3,3’-diindole methane, especially in oral form, resulting in low absorption and utilization efficiency in vivo.
Using polymer whey protein encapsulation technology, glutathione and 3,3'-diindolemethane are encapsulated by specific heat treatment and pH adjustment methods to form a microencapsulated form to improve their stability in the digestive tract. and absorption efficiency.
The bioavailability and stability of glutathione and 3,3’-diindole methane is significantly improved, its antioxidant activity and pharmacokinetics in the body are improved, and it provides better protection and delivery effects.
Smart Images

Figure CN118976005A_ABST
Abstract
Description
[0001] This application is a divisional application of an application with an application date of August 17, 2021, application number 202180066551.6, and invention name “Antioxidant compounds encapsulated in polymerized whey protein and preparation method thereof”. Technical Field
[0002] The present invention relates to a method for encapsulating glutathione (GSH), 3,3'-diindolylmethane (DIM), coenzyme Q10 (CoQ10) and other hydrophobic antioxidant compounds by using whey protein that can be polymerized in a specific manner. Compositions comprising polymerized whey protein encapsulated glutathione, DIM, Coenzyme Q10, etc. are described herein. background
[0003] Glutathione (GSH) is an antioxidant found in plants, animals, fungi and some bacteria. Glutathione is the most abundant thiol in animal cells, ranging from 0.5 to 10 mM. It is present in the cytosol and organelles (Guoyao Wu, Yun-Zhong Fang, Sheng Yang, Joanne R. Lupton, Nancy D. Turner. "Glutathione Metabolism and its Implications for Health," Journal of Nutrition (2004) 134 (3): 489–92).
[0004] Glutathione exists in reduced (GSH) and oxidized (GSSG) states. The ratio of reduced glutathione to oxidized glutathione in cells is a measure of cellular oxidative stress, where an increase in the ratio of GSSG to GSH indicates greater oxidative stress (A. Pastore, et al., "Determination of blood total, reduced, and oxidized glutathione in pediatric subjects". Clinical Chemistry (August 2001) 47(8):1467–9; SC Lu. "Glutathione synthesis". Biochimica et Biophysica Acta (BBA)-General Subjects (May 2013) 1830(5):3143–53). In healthy cells and tissues, more than 90% of the total glutathione pool is in the reduced form (GSH), and the rest is in the disulfide form (GSSG); (KM Halprin, A. Ohkawara "The measurement of glutathione in human epidermis using glutathione reductase". The Journal of Investigative Dermatology (1967) 48 (2): 149-52).
[0005] GSH protects cells by neutralizing (i.e. reducing) reactive oxygen species. The reduction of peroxides illustrates this transformation:
[0006] 2 GSH+R2O2→GSSG+2 ROH(R=H, alkyl)
[0007] Additionally, free radicals can be quenched in vivo:
[0008] GSH+R → 0.5 GSSG+RH
[0009] Additionally, glutathione plays a key role in cell regulation and metabolism. With respect to these key metabolic and cellular roles, it would be advantageous to provide glutathione in a stable and bioavailable composition.
[0010] Glutathione lacks oral bioavailability in the digestive tract. Previous encapsulation technologies have been developed that primarily use lipid encapsulation (such as lecithin) in combination with synthetic chemicals (such as polysorbate 80) to increase the absorption of poorly absorbed compounds, but until now, the use of whey protein or polymerized whey protein has not been applied in this way. Therefore, a safe, synthetic chemical-free option is needed to improve bioavailability.
[0011] If a way can be found to improve the stability and reduce the degradation of glutathione in compositions for delivery to mammals, particularly human subjects, this would be a useful contribution to the art. In addition, if a way can be found to optimize the absorption of glutathione and its utilization by the body, such as to increase bioavailability, this would be a further useful contribution to the art.
[0012] For encapsulation of nutrients, certain film-forming compounds and surfactants are useful, for example, polyvinyl pyrrolidone, polyoxyethylene stearate, sodium cholate, deoxycholate and taurocholate phosphatidylcholine, dioleoylphosphatidylcholine, phosphatidylglycerol, dioleoylphosphatidylglycerol, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, phosphatidylethanolamine, phosphatidylserine, sphingomyelin, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylethylcellulose, one or more of which can be blended with lecithin.
[0013] 3,3'-Diindolylmethane ("DIM") is an active metabolite of indole-3-carbinol derived from cruciferous vegetables and exhibits broad-spectrum anticancer properties. The stability of DIM is a major challenge in the pharmaceutical industry. In addition, DIM has poor oral bioavailability due to its low solubility and high lipophilicity. Encapsulation by whey protein to develop nanoparticles with controlled size and properties is known, which can provide protection, preservation and delivery of sensitive compounds such as aromatic compounds or nutraceuticals.
[0014] Certain methods of encapsulating 3,3'-diindolylmethane ("DIM") and similar substances using ultrasound are known. See, A. Khan, et al., "Physicochemical and Microstructural Properties of Polymerized Whey Protein Encapsulated 3,3'-Diindolylmethane Nanoparticles," Molecules (2019) 24:702.
[0015] It would be a contribution to the chemical and formulation arts if a way could be found to improve the encapsulation process to provide, for example, polymerized whey protein encapsulated DIM with better stability, solubility and other improved properties such as oral bioavailability. SUMMARY OF THE INVENTION
[0016] A composition is described comprising polymerized whey protein encapsulating glutathione.
[0017] A method for preparing polymerized whey protein microencapsulated glutathione is described, the method comprising the steps of: dissolving whey protein concentrate powder in water at about 8%-12% w / v to provide an aqueous solution; heating the whey protein concentrate solution to at least 80°C for about 15-25 minutes to provide a polymerized whey protein solution; adding an antioxidant compound to the polymerized whey protein solution during the cooling process; stirring with a homogenizer or shear mixer to provide a clear, uniform solution; and isolating the polymerized whey protein microencapsulated antioxidant compound, for example by freeze drying or spray drying, to provide a powder.
[0018] In addition, a method for preparing polymerized whey protein microencapsulated DIM (PWP-DIM) is described, which includes the following steps: (a) dissolving whey protein concentrate powder at 10% w / v in water to provide an aqueous solution; (b) heating the whey protein concentrate solution to at least about 70°C-80°C to provide a polymerized whey protein solution; (c) adding DIM to the polymerized whey protein solution; (d) adjusting the pH in the range of about 6.5 to about 9.0; (e) cooling the polymerized whey protein solution; (f) stirring during cooling from about 80°C to about 45°C to provide a clear homogeneous solution; and (g) isolating the polymerized whey protein microencapsulated DIM.
[0019] One objective is to prepare PWP-DIM that has significantly better encapsulation to better protect it during passage through the digestive tract (ie, the gastrointestinal tract).
[0020] Another object is to prepare PWP-DIM with improved absorption in the digestive tract.
[0021] In addition, a method for preparing polymerized whey protein microencapsulated antioxidant compounds is described, which includes the steps of: (a) dissolving whey protein concentrate powder at 10% w / v in water to provide an aqueous solution; (b) heating the whey protein concentrate solution to about 70°C-80°C for about 15 minutes to provide a polymerized whey protein solution; (c) adding glutathione to the polymerized whey protein solution; (d) stirring to provide a clear homogeneous solution; and (e) isolating the polymerized whey protein microencapsulated glutathione, for example by freeze drying, to provide a powder.
[0022] In one embodiment, the method for preparing polymerized whey protein microencapsulated antioxidant compounds is used to prepare polymerized whey protein microencapsulated glutathione (PWP-GSH).
[0023] In another embodiment, the method for preparing polymerized whey protein microencapsulated antioxidant compounds is used to prepare polymerized whey protein microencapsulated coenzyme-Q10 (PWP-CoQ10). BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 Depicted is a standard curve for the determination of reduced glutathione (GSH) using HPLC. The standard curve was plotted as a function of concentration versus peak area.
[0025] Figure 2 A standard curve for the determination of reduced glutathione (GSH) using the assay kit is depicted. Standard solutions were plotted as absolute OD values versus GSH concentration (μM).
[0026] Figure 3 Depicted are the plasma concentrations of reduced glutathione (GSH) (μmol / L) as a function of time after oral administration of the test samples to mice.
[0027] Figure 4 A standard curve for determining the antioxidant activity of plasma was plotted. The standard curve was drawn by determining the OD values of different standard samples at 0.1, 0.2, 0.4, 0.8 and 1.0 mM.
[0028] Figure 5 Depicted is the in vivo antioxidant activity of mouse plasma after oral administration of free GSH, WPC / PWPC-based GSH, WPC / PWPC as measured by an assay kit (ABTS method) in the Examples. The order of the vertical bars at a single time point from left to right: control, WPC, PWP, GSH, WPC-GSH, and PWP-GSH.
[0029] Figures 6A-6F Depicted is the GSH concentration (μM) in mouse tissues measured after oral administration of free GSH, WPC / PWPC-based GSH, WPC / PWPC in another example. The order of the vertical bars at a single time point from left to right: control, WPC, PWP, GSH, WPC-GSH, and PWP-GSH. Figures 6A-6F Measurements of brain (A), heart (B), lung (C), kidney (D), liver (E), and intestine (F) are shown.
[0030] Figure 7 In another example, the body weight curve in grams of rats in a 28-day feeding test in which PWP-GSH was incorporated into the diet is depicted.
[0031] Figure 8 In another example, food consumption curves in grams / rat / day for rats in a 28-day feeding test in which PWP-GSH was incorporated into the diet are depicted.
[0032] Fig. 9 In another example, food efficiency curves of rats in a 28-day feeding test in which PWP-GSH was incorporated into the diet are depicted.
[0033] Fig. 10A Depicted are microscopic images of stained sections of several organ tissues of male rats in a 28-day feeding test in which the feed was spiked with 4% by weight of PWP-GSH compared to a control in the Examples.
[0034] Fig. 10B Depicted are microscopic images of stained sections of several organ tissues of female rats in a 28-day feeding test in which feed was spiked with 4% by weight of PWP-GSH compared to a control in the Examples.
[0035] Fig.11 A standard curve for determining the reduced glutathione (GSH) content in a solid sample using a reduced glutathione (GSH) assay kit (A006-2-1) is depicted.
[0036] Fig.12 TEM images of PWPC and PWPC-GSH determined using standard techniques are depicted. The scale at the bottom is 1.0 micrometer.
[0037] Fig.13A Particle size distribution of WPC-based whey protein encapsulated glutathione nanoparticles (eg, PWPC-GSH) is depicted.
[0038] Fig. 13B Particle size distribution of WPI-based whey protein encapsulated glutathione nanoparticles (eg, PWPI-GSH) is depicted.
[0039] Fig.14 Depicted are the polydispersity indices (PDI) of whey protein encapsulated glutathione nanoparticles (eg, PWPI-GSH) based on WPC and WPI starting materials. Letters ac mean significant (P≤0.05).
[0040] Fig.15 Depicted are the zeta potentials (mV) of whey protein encapsulated glutathione nanoparticles (eg, PWPI-GSH) based on WPC and WPI starting materials. Letters ad mean significant (P≤0.05).
[0041] Fig.16A The apparent viscosity (mPa-sec) of WPC-based whey protein encapsulated glutathione nanoparticles (eg, PWPC-GSH) is depicted versus shear rate (1 / s).
[0042] Fig. 16B The apparent viscosity (mPa-sec) of WPI-based whey protein-encapsulated glutathione nanoparticles (eg, PWPI-GSH) is depicted versus shear rate (1 / s).
[0043] Fig.17APlotted circular dichroism of WPC-based whey protein encapsulated glutathione nanoparticles (e.g., PWPC-GSH) x 10 3 deg cm 2 dmol -1 Compared to wavelength (nm).
[0044] Fig. 17B Circular dichroism of WPI-based whey protein encapsulated glutathione nanoparticles (e.g., PWPI-GSH) x 10 3 deg cm 2 dmol -1 Compared to wavelength (nm).
[0045] Fig.18A Depicted is the FT-IR spectrum of WPC-based whey protein encapsulated glutathione nanoparticles (eg, PWPC-GSH) obtained using standard techniques.
[0046] Fig.18B Depicted is the FT-IR spectrum of WPI-based whey protein encapsulated glutathione nanoparticles (eg, PWPI-GSH) obtained using standard techniques.
[0047] Fig.19 Depicted are the average particle sizes (nm) of PWPI standards, PWPI-CoQ10 samples at ratios of 100:1, 80:1, 60:1, 40:1, and 20:1 (PWPI:CoQ10) measured by standard methods.
[0048] Fig. 20 Depicted are the polydispersity index (PDI) of PWPI standards, PWPI-CoQ10 samples measured by standard methods at ratios of 100:1, 80:1, 60:1, 40:1, and 20:1 (PWPI:CoQ10).
[0049] Fig.21 Depicted are the zeta potentials (mV) of PWPI standards, PWPI-CoQ10 samples measured by standard methods at ratios of 100:1, 80:1, 60:1, 40:1, and 20:1 (PWPI:CoQ10).
[0050] Specific description
[0051] In one aspect, the present invention relates to microencapsulation of both fat and water-soluble antioxidants with polymerized whey protein, with the explicit purpose of protecting nutrients from degradation and optimizing absorption and utilization in vivo. For example, the present inventors have contributed to and described the method of preparing polymerized whey protein-encapsulated glutathione (PWP-GSH) of the present invention in the following: S. Zhang, et al., "Polymerized Whey Protein Concentrate-Based Glutathione Delivery System: Physicochemical Characterization, Bioavailability and Sub-Chronic Toxicity Evaluation," Molecules (2021) 26: 1824, which is hereby incorporated by reference in its entirety.
[0052] In a further aspect, the present invention relates to a novel method for manipulating whey protein by adjusting temperature and pH to allow protein to be encapsulated around nutrients (particularly antioxidants) for protection and optimal absorption and utilization. Antioxidants that have been successfully encapsulated using the method of the present invention are glutathione, diindolylmethane and coenzyme Q10. Current research is being conducted to apply this technology to dietary supplements (e.g., tableting, encapsulation, incorporation into ready-to-drink powders) and allow antioxidants to be successfully incorporated into a variety of foods and beverages to increase the health benefits of food or beverages.
[0053] An advantage of the current method is that a technically simplified and more natural process is achieved without the use of certain chemical agents that are typically undesirable by natural food or dietary supplement companies.
[0054] In the main embodiments, the encapsulation of antioxidant compounds and other derivatives is more uniform, which allows for better protection of the active ingredients in the digestive tract. In addition, the method embodiments provide better encapsulation when viewed from a microscope, such as using SEM or TEM.
[0055] When compared to free GSH, the PWP-GSH compositions and formulations described herein show improved in vivo absorption, better pharmacokinetics, better bioavailability and higher antioxidant capacity. When compared to comparator GSH products, the PWP-GSH compositions and formulations described herein also show improved in vivo absorption, better pharmacokinetics and better bioavailability.
[0056] Microencapsulation
[0057] Microencapsulation is a technology used to protect a variety of biomolecules. See, Whey Protein Production, Chemistry, Functionality, and Applications, ed. Mingruo Guo (one of the inventors of the present invention), Chapter 7, "Whey Protein Functional Properties and Applications in Food Formulation," pp. 157-204 (and references cited therein), (Wiley: Hoboken, NJ, 2019), which is incorporated herein by reference.
[0058] The formulations can be prepared in any product form suitable for human subjects, including reconstitutable powders, ready-to-feed liquids, parenteral (intravenous) formulations, and dilutable liquid concentrates, all of which are well known in the field of nutritional formulas. As used in this application, the amount of a component present in a formulation or composition refers to the amount when the formulation or composition is ready for consumption by a human subject.
[0059] The formulation or composition may be optionally sterilized and then used on a ready-to-eat basis, or may be stored as a concentrate. A concentrate may be prepared by spray drying a liquid formulation prepared as above, and the formulation may be reconstituted by rehydrating the concentrate. The formulation concentrate is a stable liquid and has a suitable shelf life.
[0060] For powder embodiments of the formulations or compositions comprising GSH, whey protein encapsulated GSH (WP-GSH) or polymerized whey protein encapsulated GSH (PWP-GSH) used in the methods of the present invention, the powder can be reconstituted with a suitable aqueous liquid, preferably water. Reconstituted powders are typically in the form of flowable or substantially flowable granular compositions, or at least specific compositions that can be easily scooped and measured with a spoon or other similar device, wherein these compositions can be easily reconstituted by the intended user with a suitable aqueous fluid (typically water) to form a liquid formulation or composition. In this case, "immediate" use generally means within about 48 hours, most typically within about 24 hours, preferably immediately after reconstitution. These powder embodiments include spray drying, agglomeration, dry mixing or other known or other effective granular forms. The amount of nutritional powder required to produce a volume suitable for a serving size can vary.
[0061] The nutritional formulas used in the methods of the present invention can be packaged and sealed in single or multiple use containers and then stored at ambient conditions for up to about 36 months or longer, more typically from about 12 to about 24 months. For multiple use containers, these packages can be opened by the end user and then covered for repeated use, provided that the covered package is then stored at ambient conditions (e.g., avoiding extreme temperatures) and the contents are used within about a month or so.
[0062] Compositions for oral formulations for delivery of dietary supplement compositions (comprising GSH, whey protein encapsulated GSH (WP-GSH) or polymerized whey protein encapsulated GSH (PWP-GSH)) can be administered orally, for example, together with an inert diluent or together with an absorbable edible carrier, or can be encapsulated in a hard or soft shell gelatin or hydroxypropyl methylcellulose (i.e., hypromellose) capsule, or can be compressed into tablets, or can be incorporated directly into the food of the diet. For oral administration, dietary compositions comprising GSH, whey protein encapsulated GSH (WP-GSH) or polymerized whey protein encapsulated GSH (PWP-GSH) can be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, lozenges, capsules, elixirs, suspensions, syrups, wafers, and the like. Tablets, lozenges, pills, capsules, etc. may also contain the following: binders, such as tragacanth, gum arabic, corn starch or gelatin; excipients, such as dicalcium phosphate, microcrystalline cellulose, etc.; disintegrants, such as potato starch, alginic acid, etc.; lubricants, such as magnesium stearate; and sweeteners (such as sucrose, lactose or saccharin) or flavorings (such as mint, wintergreen oil or cherry flavoring) may be added. When the dosage unit form is a capsule, it may contain a liquid carrier in addition to the above-mentioned types of materials. Various other materials may exist as a coating or otherwise modify the physical form of the dosage unit. For example, tablets, pills or capsules may be coated with shellac, sugar or both. Syrups or elixirs may contain active compounds, sucrose as a sweetener, methylparaben and propylparaben as preservatives, dyes, and flavorings such as cherry or orange flavors. Oil-in-water emulsions may be better for oral use by infants because they are water miscible, so their oiliness is masked. Such emulsions are well known in pharmaceutical science.
[0063] Determination of GSH using HPLC
[0064] Optimal conditions for HPLC analysis:
[0065] Column: symmetry C18
[0066] Mobile phase: water: acetonitrile = 90:10
[0067] Flow rate: 0.5 ml / min
[0068] Wavelength: 218 nm (UV detector)
[0069] Injection volume: 0.5 μL
[0070] GSH powder was dissolved in ultrapure water to prepare a 10 mg / ml stock solution. A series of standard solutions (0.2 mg / ml, 0.4 mg / ml, 0.6 mg / ml, 0.8 mg / ml, 1.0 mg / ml) were obtained by diluting the stock solution with ultrapure water. GSH was determined using HPLC. Figure 1 The standard curve was plotted as a function of concentration and peak area as shown.
[0071] The compositions and methods described in the above embodiments can be further understood in connection with the following examples. In addition, the following non-limiting examples are provided to illustrate the present invention. However, it will be appreciated by those skilled in the art that it may be necessary to change the procedure for any given embodiment of the present invention, for example, to change the order or steps of the method.
[0072] Example 1
[0073] Whey protein–GSH blend (WP-GSH)
[0074] Whey protein concentrate (WPC) solution (10% protein, w / v) was prepared by dissolving whey protein concentrate powder in deionized water at room temperature and then stirring (700 rpm) for 2 h. The stock solution was stored at 4 ° C overnight for complete hydration. The whey protein solution was warmed to ambient temperature and then mixed with reduced GSH in a weight ratio of WPC (powder): GSH = 1:1, 1:1.5 and 1:2. The mixture was stirred for 20 min to achieve complete dissolution.
[0075] Polymerized whey protein encapsulated GSH (PWP-GSH)
[0076] Whey protein concentrate (WPC) solution (10% protein, w / v) was prepared by dissolving whey protein concentrate powder in deionized water at room temperature and then stirring (700 rpm) for 2 h. The solution was stored at 4 ° C overnight to fully hydrate. The whey protein solution was returned to ambient temperature and the pH was adjusted to 7 or 8, then heated at 80 ° C for 15 min. The polymerized whey protein (PWPC) solution was obtained by rapidly cooling the heated whey protein solution to room temperature (25 ° C ± 1 ° C) in mixed water-ice. The PWPC solution was then mixed with GSH powder in a weight ratio of PWPC:GSH=1:1, 1:1.5 and 1:2. The mixture was mixed for 20 min to achieve complete dissolution.
[0077] Stability test
[0078] The stability of all whey protein based GSH solutions was observed at room temperature for 20 h. Table 1 below lists the stability of whey protein based glutathione solutions (including polymeric examples).
[0079] Table 1
[0080]
[0081]
[0082]
[0083] As shown in Table 1, the PWP-GSH samples were stable to at least 4 hours.
[0084] Example 2
[0085] Pharmacokinetic studies
[0086] ICR mice (male, SPF, 3 weeks, weighing 18 to 22 g) were provided by Beijing HFK Bioscience Co., Ltd (Beijing, China). Reduced glutathione (GSH) assay kit (A006-2-1) and total antioxidant capacity measurement kit (ABTS method) (A015-2-1) were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, Jiangsu, China).
[0087] All mice were housed in plastic laboratory animal cages in a ventilated room. The room was maintained at 20°C ± 2°C and 60% ± 10% relative humidity with a 12 h light / dark cycle. Water and commercial laboratory complete food for mice were freely available. They were acclimated to this environment for 7 days before handling. All animal experiments were approved by the Animal Welfare and Research Ethics Committee of Jilin University (Approval No.: SY201905018).
[0088] Blood collection. Before blood collection, add 30 μL of heparin solution to a 1.5 mL centrifuge tube and vortex. Collect blood samples (about 0.5 mL) by removing one eye of the mouse. Centrifuge the blood at 6000 rpm for 2 min at room temperature. Transfer the upper plasma to a new centrifuge tube. Analyze plasma GSH concentration using a GSH assay kit.
[0089] The GSH stock solution (1 mmol / L) was diluted into a series of standard solutions with concentrations of 0 μmol / L, 5 μmol / L, 10 μmol / L, 20 μmol / L, and 100 μmol / L. The standard solutions were plotted as absolute OD values versus GSH concentration ( Figure 2 ).
[0090] A. After oral administration of free GSH, whey protein-based GSH, whey protein, polymerized whey protein-based GSH and polymerized whey protein by gavage in 6 mice per group at several time points (0, 15 min, 30 min, 1 h, 2 h and 4 h), blood samples were collected. The dose of whey protein-based GSH was adjusted to an equivalent of 100 mg / kg of GSH. The GSH concentration in the blood samples was determined by an assay kit.
[0091] Table 2 shows the test groups and gavage volumes.
[0092] Table 2
[0093]
[0094] like Figure 3 As shown in , the PWP-GSH test material provided an excellent and significant increase in GSH concentration in plasma after oral administration.
[0095] B. Antioxidant activity in vivo
[0096] The Trolox stock solution (10 mM) was diluted to 0.1, 0.2, 0.4, 0.8, and 1.0 mM. The standard curve was drawn by determining the OD values of different standard samples ( Figure 4 The antioxidant activity of plasma was expressed as a multiple of the capacity of Trolox, where the TAOC (total antioxidant capacity) of Trolox was 1.
[0097] The total antioxidant capacity of all samples was also measured using an assay kit and the results were as Figure 5 The in vivo antioxidant activity of plasma after oral administration of free GSH, WPC / PWPC-based GSH, and WPC / PWPC to mice was measured by an assay kit (ABTS method).
[0098] like Figure 5 As shown in , the PWP-GSH sample showed the most robust antioxidant activity over time.
[0099] C. Tissue distribution of GSH
[0100] To evaluate the delivery efficiency of GSH to organs, tissue samples of brain, heart, kidney, liver, lung and intestine were collected at 0, 1, 2, 4 and 6 h after oral administration from 6 mice in each group. The tissues were homogenized, proteins were precipitated, centrifuged, and then analyzed for GSH content using an assay kit ( Fig. 6A –6F).
[0101] like Figures 6A-6F As shown, the distribution of free GSH in various tissues was significantly greater than that in the control. In addition, the distribution of GSH in various tissues in the PWP-GSH group was significantly greater than that in the control.
[0102] D. Toxicity study of polymerized whey protein-based GSH (PWP-GSH)
[0103] Whey protein concentrate was provided by Fonterra Co-operative Group (Auckland, New Zealand). Sodium pentobarbital, formalin and anhydrous ethanol were provided by Beijing Works (Beijing, China). 3-week-old SD rats were provided by Beijing Huafukang Biotechnology Co., Ltd. (Beijing, China).
[0104] Dietary preparations
[0105] According to Example 1, GSH (PWP-GSH) based on polymerized whey protein concentrate was prepared, wherein the polymerized whey protein concentration was 10%, and the ratio of whey protein to GSH was 1: 1. The prepared polymerized whey protein GSH was then dried using a freeze dryer (German Alpha 1-4LDplus). Then the GSH based on powdered polymerized whey protein was mixed into normal feed at a percentage of 0.5%, 1% and 4% (w / w) (corresponding to a GSH percentage of 0.25%, 1% and 2%). These diets were prepared by Beijing Huafukang Biotechnology Co., Ltd. (Beijing, China). The dosage was set based on the daily intake of healthy people (100 mg / day). Calculated with an average weight of 60 Kg, the dosage for people was 1.6 mg / kg. According to the conversion formula, this is equivalent to 10 mg / kg for rats. The dosage was set to 0.5%, 1% and 4%, which corresponds to 25, 50 and 200 times the daily intake of people.
[0106] Experimental design
[0107] Eighty 3-week-old rats (half male and half female) were purchased from Beijing Huafukang Biotechnology Co., Ltd. (Beijing, China). All rats were housed in plastic laboratory animal cages in a ventilated room. The room was maintained at 20°C ± 2°C and 60% ± 10% relative humidity with a 12 h light / dark cycle. Water was freely available. Before treatment, the rats were acclimated to the environment for 7 days, with no significant changes in general status. After acclimation, the rats were randomly divided into four groups (10 / sex / group) based on the mean body weight. At the time of randomization, the individual body weights in the groups were within ± 20% of the overall mean. Compared with the animals in the control group, the low-, medium-, and high-dose group animals received 0.5%, 1%, and 4% whey protein-based GSH in their diets, respectively. All animal experiments were approved by the Animal Welfare and Research Ethics Committee of Jilin University (Approval No.: SY201905018).
[0108] Clinical observation
[0109] Throughout the study, each rat was observed for changes in hair condition, skin, mucous membranes, secretions and excretions, autonomic nervous system activity, gait, and posture.
[0110] Body weight and food intake
[0111] Individual body weights and body weights at intervals of 4 days were weighed and recorded for a total of 28 days. Final body weights (fasted) were recorded before planned autopsy. Feed intake was also measured and expressed as the average food consumption (expressed as g / rat / day) calculated for the corresponding time intervals.
[0112] Blood collection
[0113] At the end of the experiment, all animals were fasted for 12 h before blood collection, but they did have access to water. 2% sodium pentobarbital solution was injected into rats at a level of 0.2 ml / 100 g. Then, two separate blood samples for hematology and serum chemistry were collected via the heart. For hematological analysis, blood samples were collected through EDTA-2K coated tubes, and then Exigo animal hematology analyzer was used to determine white blood cells (WBC), red blood cells (RBC), hemoglobin (HGB), hematocrit (HCT), platelet count (PLT), mean corpuscular volume (MCV), mean corpuscular hemoglobin content (MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell volume distribution (RDW), mean platelet volume (MPV), lymphocytes (LYM), neutrophils (GRAN), monocytes (MONO), lymphocyte percentage (LYM%), granulocytes (GRA), monocyte percentage (MON%).
[0114] For serum chemistry analysis, blood samples were centrifuged at 10000 rpm for 3 min at room temperature. The upper serum layer was transferred to a new centrifuge tube, and then albumin (ALB), calcium (Ca), creatinine (Crea), total bilirubin (TB), total protein (TP), inorganic phosphorus (PHOS), urea (UREA), amylase (AMY), triglyceride (TG), glucose (GLU), BUN to CR ratio (U / C), creatine kinase (CK), globulin (GLOB), aspartate aminotransferase (AST) were determined using a Smt-120v automatic biochemical analyzer.
[0115] Organ weights, gross necropsy, and histopathology
[0116] At the end, all rats were anesthetized by sodium pentobarbital and bled by transverse thoracic cavity.Then complete macroscopic pathological examination was performed by visual inspection during autopsy.The brain, heart, lung, liver, spleen, kidney, bladder, ovary, uterus, testis, epididymis and seminal vesicle of all animals were excised and weighed.The relative weight of each organ (or paired organ) was calculated based on the final individual body weight measured on the same day of the end.Except that the testis was fixed with Bouin solution, the tissue sections of these organs were fixed with 10% buffered formaldehyde, embedded in paraffin, sliced with 2-5 μm, sealed on glass microscope slides, stained with standard hematoxylin-eosin, and examined using an optical microscope.All histopathological procedures were carried out at Jilin University Animal Science and Veterinary College (College of Animal Science and Veterinary Medicine, Jilin University).
[0117] result
[0118] During the course of the experiment, no adverse effects were observed in the experimental group compared to the control group.
[0119] During the course of the experiment, no signs of adverse effects in the clinical appearance of the animals related to the treatment were observed. As the treatment period progressed, body weight gradually increased ( Figure 7 ). There were no statistically significant differences in body weight between the female groups. For the male group, starting from day 16, 1% of the male group was significantly different from those of the control. Body weight changes were observed only in the male group, and there was no dose-dependent effect.
[0120] Figure 8 and Fig. 9The 28-day results of food consumption and food efficiency of rats are shown in Figure 2. No PWPC-GSH-related toxic effects were observed in the experimental groups, although there were some significant differences between the experimental groups and the control at some time points. On day 8, the food efficiency of the 0.5% and 4% female groups showed significant differences compared to the control (p<0.05).
[0121] Table 3 shows the serum biochemistry of male rats in the 28-day toxicity study.
[0122] Table 3
[0123]
[0124]
[0125] Note: * means a significant level of 0.05 compared with the control group, ** means a significant level of 0.01 compared with the control group
[0126] The serum biochemistry results of male rats are shown in Table 3 above. Albumin in the 4% male group showed a value of 33.01±1.34 g / L, which was significantly lower than that of the control group (p<0.05). The low albumin content in the serum may be due to a synthetic defect. There may be two reasons for this change. Due to hepatitis, the absorption of albumin by the liver may be reduced. Another reason may be the renal excretion disorder caused by low nephrogenicity, which may cause a large amount of albumin to be excreted with urine. Globulin in 4% males was 28.1±2.77 g / L, which was significantly lower than that of the control group (p<0.05). However, this value is within the normal range (15-28g / L). Aspartate aminotransferase in 4% males was 91.17±8.13 U / L, which was significantly lower than that of the control group (p<0.05). However, this value is also within the normal range (39-111 U / L). Alanine aminotransferase in the 4% males was 39 ± 7.73 U / L, which was significantly lower than the value in the control group (p<0.05). However, this value was within the normal range (20-61 U / L). Aspartate aminotransferase and alanine aminotransferase are indicators of liver function. An increase in these two parameters may indicate some pathological changes in the liver, while a decrease may not be clinically significant. Amylase values in all experimental groups were significantly reduced compared with the control (p<0.05), which is a benefit. Creatine kinase values in the experimental groups were significantly lower than those in the control group (p<0.05), which is a benefit. Glucose in the 4% males was significantly lower than that in the control group and was within the normal range (2.78-7.50 μmol / L). Calcium levels in the 1% and 4% male groups were significantly lower than those in the control group (p<0.05). The decrease in calcium levels may be due to (1) parathyroid hormone deficiency; (2) vitamin D deficiency or metabolic abnormalities; (3) chronic kidney disease.
[0127] In summary, significant changes in serum biochemistry were mainly observed in the 4% male group, and these changes were mainly related to the function of the liver or kidney.
[0128] Table 4 shows serum biochemistry of female rats in the 28-day toxicity study (n=10).
[0129] Table 4
[0130]
[0131]
[0132] Note: * means the significance level is 0.05 compared with the control group, ** means the significance level is 0.01 compared with the control group
[0133] The serum biochemistry results of female rats are shown in Table 4. The total protein in the 1% female group was 68.02±4.31 g / L, which was significantly higher than the value in the control group (p<0.05). However, it was within the normal range (53-69 g / L). The elevated total protein level may be due to chronic liver disease. Amylase and glucose in the 1% and 4% females were significantly lower than those in the control group (p<0.05). The levels of inorganic phosphorus in the 1% and 4% female groups were significantly higher than those in the control group. However, they were within the normal range (1.87-3.6 μmol / L).
[0134] hematology
[0135] Table 5 shows the hematology of male rats in the 28-day toxicity study (number of animals = 10).
[0136] Table 5
[0137]
[0138]
[0139] Note: * means the significance level is 0.05 compared with the control group, ** means the significance level is 0.01 compared with the control group
[0140] PWPC-GSH powder had no treatment-related adverse effects on hematological parameters in male rats. However, some statistically significant differences between the control and treatment groups emerged. PLT, MPV in the 4% group were significantly different from those of the control (p<0.05). MPV and LYM in the 0.5% group were also significantly different from those of the control (p<0.05).
[0141] Table 6 shows the hematology of female rats in the 28-day toxicity study (number of animals = 10).
[0142] Table 6
[0143]
[0144]
[0145] Note: * means the significance level is 0.05 compared with the control group, ** means the significance level is 0.01 compared with the control group
[0146] PWPC-GSH powder had no treatment-related adverse effects on hematological parameters in female rats. However, some statistically significant differences emerged between the control and treated groups. RBCs in the 1% group showed 6.76±0.56×10 12 The HGB values in the 1% female group (14.46 ± 0.88 g / dL) and the 4% female group (14.10 ± 0.36 g / dL) were significantly higher than those in the control group (p < 0.05). However, these values are within the normal range (13.2-16.4 g / dL) and should not be considered as adverse effects.
[0147] Relative organ weight
[0148] The results of relative organ weights are shown in Tables 7 and 8. The final body weight of male rats using PWPC-GSH powder was significantly lower than that of the control group (p<0.05). Compared with the control, the relative weights of all organs of rats fed with PWPC-GSH powder were not significantly different, except for the liver and kidney in the 4% male group.
[0149] Table 7 shows the relative organ weights of male rats in the 28-day toxicity study (number of animals = 10).
[0150] Table 7
[0151]
[0152]
[0153] Note: * means the significance level is 0.05 compared with the control group, ** means the significance level is 0.01 compared with the control group
[0154] For female rats, the final body weight of rats in the 4% group was significantly reduced (p<0.05).There were no significant differences in relative organ weights between rats fed with PWPC-GSH powder and the control group.
[0155] Table 8 shows the relative organ weights of female rats in the 28-day toxicity study (number of animals = 10).
[0156] Table 8
[0157]
[0158] Note: * means the significance level is 0.05 compared with the control group, ** means the significance level is 0.01 compared with the control group
[0159] Pathology and Histopathology
[0160] Fig. 10A and 10B Stained sections of several tissues of male and female rats in the 4% fed group compared to controls are shown. Tissue samples were prepared and stained by conventional methods and observed by standard microscopic methods.
[0161] in conclusion
[0162] The results of the PK study showed that the serum intake of polymerized whey protein encapsulated GSH (PWP-GSH) was three times higher than that of Kyowa's Setria GSH. After 3-4 hours of administration, the GSH levels in the brain and liver tissues of rats fed with polymerized whey protein encapsulated GSH were significantly higher than those of the group fed with a commercial GSH diet. Compared with the control, there were some changes in the parameters of body weight, serum biochemistry and relative organ weight in the 4% fed male group. Therefore, it can be concluded that for male rats, the level (NOAEL) for which no adverse effects were observed was estimated to be at least 1%, and for female rats, the level was 4%, corresponding to about 50 and 200 times the daily intake value for humans.
[0163] In conclusion, the bioavailability of whey protein encapsulated GSH (WP-GSH, PWP-GSH) was greatly improved compared with the standard control and it was a safe form of delivery system.
[0164] Example 3
[0165] Preparation of polymerized whey protein encapsulated glutathione (PWP-GSH)
[0166] Whey protein concentrate (5 Kg) was dissolved in distilled water at a concentration of 10% (w / v) and stored at 4°C overnight. The whey protein concentrate solution was then heated at 80°C for 15 minutes. After cooling to room temperature, the PWPC solution was then mixed with GSH powder (5 Kg) at a weight ratio of PWPC:GSH=1:1. The mixture was stirred for 20 min to completely dissolve. After blending, the mixture was then freeze-dried to provide a PWP-GSH powder product.
[0167] Reduced glutathione (GSH) assay kit (A006-2-1), total antioxidant capacity measurement kit (ABTS method) (A015-2-1) can be obtained from Nanjing Jiancheng Bioengineering Institute (Nanjing, Jiangsu, China). Several methods can be used to determine GSH content. The following procedure provides the determination of undigested GSH content.
[0168] PWPC-based GSH powder (2 g) was dissolved in 20 mL PBS buffer and then sonicated for 20 min for complete extraction. After sonication, 1 mL of the supernatant was taken and diluted 800 times. Then, 1 mL of the diluted solution was mixed with 1 mL of protein remover and then centrifuged at 3500 rpm for 10 min. The GSH content of the supernatant was then determined using a GSH assay kit.
[0169] Alternatively, GSH content was determined after trypsin digestion.
[0170] Release solution: trypsin (10 g) with an enzyme activity of 1:250 was dissolved in 1 L of NaCl solution (0.5%, w / v) and then adjusted to pH 8 using 0.1 M NaOH solution. PWPC-based GSH powder (0.3 g) was placed in 30 mL of release solution and incubated at 37 °C while shaking at 100 rpm for 6 h. The mixture was then centrifuged at 5,000 × g for 20 min, and the supernatant was diluted 100 times. The diluted suspension was then mixed with protein removal solution at a ratio of 1:1 (v / v) and then centrifuged. The GSH content of the supernatant was then determined using a GSH assay kit.
[0171] refer to Fig.11 The standard curve shows that the OD values of the two samples without digestion were 0.2883 and 0.2862, respectively, corresponding to 43.2% and 42.9% (w / w) GSH contents in the PWPC-GSH products. After trypsin digestion, the OD values of the two samples were 0.2654 and 0.2627, respectively, corresponding to 49.8% and 49.2% (w / w) GSH contents in the PWPC-GSH products.
[0172] Therefore, the processing technology for the manufacture of whey protein encapsulated GSH (PWP-GSH) has been established, and the recovery of glutathione in the matrix was 99.2%, indicating that the loss of this thermosensitive compound was only 0.8% during the whole process.
[0173] Example 4
[0174] Chemical Characterization of PWP-GSH Samples. It is well understood that samples prepared according to the principles of the present disclosure can be characterized by various means well known in the art, including but not limited to viscosity measurements and other rheological measurements, FT-IR, TEM / SEM microscopy, microstructure and morphology studies, stability studies (solid phase, solution phase, humidity, heat), particle size, zeta potential, etc. It is expected that the chemical analysis will further demonstrate the unique qualities and characteristics of the compositions described herein. See Khan, et al., 2019.
[0175] Example 4A
[0176] 1. Preparation of PWPC-GSH using whey protein concentrate (PWC)
[0177] Compared with other supports based on polyisobutyl cyanoacrylate, Eudragit RS 100 / cyclodextrin and montmorillonite, the prepared PWPC-GSH system has the advantages of being simple, mild and free of organic solvents. In a characterization test measured according to Zhang et al. (2021), PWPC showed a bimodal pattern with two peaks at 594 nm and 4580 nm with a wide particle size distribution (span of 9.22), which is consistent with previous studies. The combination with GSH (287.83±6.18 nm) slightly increased the particle size (D50) from 1085±35.35 nm to 1115±7.07 nm, and the span decreased from 9.22±0.22 to 6.86±0.19. The zeta potential of PWPC-GSH was found to be 30.37±0.75 mV. The high surface charge imparts high stability to the PWPC-GSH system, as the strong electrostatic repulsion between molecules prevents aggregation, precipitation and flocculation. In addition, the positive surface charge of PWPC-GSH is beneficial for in vivo absorption because the cell membrane carries negative charge. The PWPC-GSH system exhibits shear-thinning behavior in the range of 1–300 s-1, indicating that the interaction between the droplets is weakened at higher shear rates.
[0178] The DSC thermogram of GSH shows an exothermic peak at 198°C and the melting peak disappears in the PWPC-GSH system, indicating that GSH is molecularly dispersed in the PWPC particles. FTIR spectral analysis shows that PWPC shows an amide I (C=O vibration) spectral peak at 1654.39 cm-1 and red-shifts after binding with GSH, indicating that PWPC changes in structure and forms intermolecular hydrogen bonds. The PWPC-GSH system shows the morphology of worm-like aggregates, with most aggregates measuring roughly 200 nm in size, up to some larger aggregates measuring about 400 nm, as determined by standard TEM imaging techniques ( Fig.12 ).
[0179] 2. In vivo pharmacokinetics and antioxidant activity of PWPC-GSH
[0180] Whey protein has been widely studied as an effective means of nutrient delivery due to its resistance to pepsin digestion, nontoxic nature, wide availability, and wide biocompatibility. Pharmacokinetic studies were conducted on the PWPC-GSH delivery system and free GSH, and the plasma GSH concentration-time curves of all groups were determined. The highest GSH concentration in the plasma was observed in the PWPC-GSH group, followed by free GSH, PWPC, and the control group. The values in the plasma of mice gavaged with PWPC-GSH were higher than those in the free GSH group, which may be due to the protective effect of the highly viscous PWPC by embedding GSH inside and preventing damage to gastrointestinal enzymes and the acidic environment. These results are consistent with previous studies that improved the bioavailability of quercetin and vitamin D by whey protein encapsulation.
[0181] The pharmacokinetic parameters were calculated using the mouse model. 最大 ) was 7.37 mg / L, and the area under the concentration-time curve (AUC) was 19.23 hx mg / L), a higher C 最大 The C (19.41 mg / L) and AUC (48.63 hx mg / L) values of the PWP-GSH group indicated that the rate and extent of GSH absorption in the blood circulation of mice was greater after administration of PWP-GSH. 最大 The AUC and AUC were 2.5-fold and 2.6-fold higher, indicating that the PWPC-GSH delivery system can effectively improve the in vivo bioavailability of GSH compared to pure GSH alone. During absorption into the intestine, whey protein as a carrier also seems to have a protective effect on GSH, which may be due to resistance to pepsin digestion. In addition to the delivery of GSH itself, supplementing whey protein can also contribute to the increase of GSH levels in the body by means of a large number of cysteine residues inherent in whey protein, which as a rate-limiting amino acid has the ability to promote the biosynthesis of GSH. Compared with the time to reach the maximum concentration in free GSH (2 h), the time to reach the maximum concentration (Tmax) (1 h) in the PWPC-GSH group is lower, indicating that the time required to reach the maximum concentration after administration is shorter. The plasma GSH concentration in the GSH group reached the highest level after 1.5 to 2 h, which is consistent with the data reported in the early literature relative to oral administration of free GSH.
[0182] The total antioxidant capacity of the samples at different time points was measured using an assay kit. During the entire time period, the antioxidant capacity of the plasma in mice gavaged with PWPC-GSH was significantly higher than that in mice gavaged with free GSH (p<0.05). The first reason for the increase in the antioxidant capacity of plasma after mice were gavaged with PWPC-GSH was that the use of PWPC as a delivery vehicle improved the GSH concentration in plasma. The second reason may be due to the antioxidant properties of whey protein. As measured by T-AOC (mM), the plasma antioxidant capacity of mice after gavage with PWPC was also slightly improved, and its degree may be consistent or inconsistent with the cumulative effect.
[0183] Example 4B
[0184] According to Examples 3, 4 and 4A, various parameters of PWPC-GSH and PWPI-GSC were measured in comparison to whey protein concentrate (WPC) and whey protein isolate (WPI) standards.
[0185] Fig.13A and 13B The particle size distribution of whey protein encapsulated glutathione nanoparticles is shown for WPC and WPI starting materials, respectively.
[0186] Fig.14 The polydispersity index (PDI) of whey protein encapsulated glutathione nanoparticles is shown for both WPC and WPI starting materials.
[0187] Fig.15 Shown are the measured zeta potentials (mV) of whey protein encapsulated glutathione nanoparticles for both WPC and WPI starting materials.
[0188] Fig.16A and 16B The apparent viscosity versus shear rate of whey protein encapsulated glutathione nanoparticles is shown for WPC and WPI starting materials, respectively.
[0189] Fig.17A and 17B Circular dichroism of whey protein encapsulated glutathione nanoparticles is shown for WPC and WPI starting materials, respectively.
[0190] Fig.18A and 18B FT-IR spectra of whey protein encapsulated glutathione nanoparticles are shown for WPC and WPI starting materials, respectively.
[0191] Example 5
[0192] Preparation of PWP-DIM. The procedure of Khan, et al. (2019) was modified as follows.
[0193] The components are added to a continuous scrape type stirred, temperature and pH controlled tank or equivalent continuous stirred type reactor (CSTR) system. In particular, the tank is jacketed and connected to a steam source. The temperature is controlled by a thermocouple. Other parts include a pH probe on the side and a thermometer at the bottom, and a mechanical stirring system.
[0194] The whey protein was dispersed and polymerized in the tank before adding the DIM.
[0195] The temperature ranged from 70°C to 95°C, and the pH ranged from 6.5-9.0.
[0196] The viscosity of the mixture of materials before and after polymerization was measured to be between 100-300 mPas and 3000 mPas.
[0197] Results and Discussion.
[0198] DIM and whey protein concentrate are opposite in hydrophobicity / hydration properties. The process is designed to encapsulate the dispersed phase (DIM) with polymerized whey protein polymer in the continuous phase. Upon stirring and heating, when the viscosity of the system reaches the desired range, the dispersed phase is suspended and encapsulated by the polymer. The two phases of the material form a continuous and consistent microgel or aggregate.
[0199] Finally, the reaction product was spray dried using standard methods and collected as an encapsulated powder.
[0200] Example 6
[0201] Chemical Characterization of PWP-DIM Samples. It is well understood that samples prepared according to the principles of the present disclosure can be characterized by various means well known in the art, including but not limited to viscosity measurements and other rheological measurements, FT-IR, TEM / SEM microscopy, microstructure and morphology studies, stability studies (solid phase, solution phase, humidity, heat), particle size, zeta potential, etc. It is expected that the chemical analysis will further demonstrate the unique qualities and characteristics of the compositions described herein. See Khan, et al., 2019.
[0202] Example 7
[0203] In a similar manner, polymerized whey protein encapsulated Coenzyme-Q10 (PWP-CoQ10) was prepared by the above method using whey protein isolate (WPI) and characterized as an orange flaky powder. Assay (HPLC): 20.69% by weight.
[0204] like Fig.19 , 20As shown in Figures 2 and 21, PWP-CoQ10 with various ratios ranging from 20:1 (PWPI:CoQ10) to 100:1 (PWPI:CoQ10) were characterized by particle size (nm), polydispersity index (PDI) and zeta potential (mV), respectively.
[0205] In the context of describing the presently claimed invention (especially in the context of the claims), the use of the terms "a, an", "the", and similar referents should be interpreted to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by the context. Unless otherwise indicated herein, the recitation of ranges of values herein is intended merely to serve as a shorthand method of referring individually to each individual value falling within the range, and each individual value is incorporated into the specification as if it were individually stated herein. The use of the term "about" is intended to describe values that are within a range of approximately ±10% above or below the stated value; in other embodiments, these values may range within a range of approximately ±5% above or below the stated value; in other embodiments, these values may range within a range of approximately ±2% above or below the stated value; in other embodiments, these values may range within a range of approximately ±1% above or below the stated value. The above ranges are intended to be determined according to the context, and no further limitation is implied. All methods described herein can be performed in any suitable order, unless otherwise indicated herein or clearly contradicted by the context. The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better describe the present invention and does not limit the scope of the present invention unless otherwise stated. No language in the specification should be construed as indicating that any unclaimed element is essential to the practice of the present invention.
[0206] Although in the foregoing specification, the present invention has been described with respect to certain embodiments thereof and many details have been presented for the purpose of illustration, it will be apparent to those skilled in the art that the present invention is susceptible to other embodiments and that certain details described herein may be considerably modified without departing from the basic principles of the present invention.
[0207] All references cited herein are incorporated by reference in their entirety. The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof, and therefore reference should be made to the appended claims indicating the scope of the invention rather than to the foregoing description.
[0208] The present invention also provides the following items:
[0209] 1. A composition comprising polymerized whey protein encapsulating an antioxidant compound selected from the group consisting of 3,3'-diindolylmethane (DIM), glutathione (GSH) and coenzyme-Q10 (CoQ10).
[0210] 2. The composition according to item 1, wherein the polymerized whey protein is a polymerized whey protein concentrate.
[0211] 3. The composition of claim 2, wherein the ratio of the polymerized whey concentrate to the antioxidant compound is in the range of about 2:1 (wt / wt) to about 10:1 (wt / wt).
[0212] 4. A method for preparing polymerized whey protein microencapsulated 3,3'-diindolylmethane (DIM), the method comprising the following steps:
[0213] (a) dissolving whey protein concentrate powder at 10% w / v in water to provide an aqueous solution;
[0214] (b) heating the whey protein concentrate solution to at least about 70° C. to 80° C. to provide a polymerized whey protein solution;
[0215] (c) adding DIM to the polymerized whey protein solution;
[0216] (d) adjusting the pH to within the range of about 6.5 to about 9.0;
[0217] (e) cooling the polymerized whey protein solution;
[0218] (f) stirring during cooling from about 80° C. to about 45° C. to provide a clear homogeneous solution; and
[0219] (g) Isolation of polymerized whey protein microencapsulated DIM.
[0220] 5. The method of item 4, wherein whey protein concentrate and DIM are used in equal amounts by weight.
[0221] 6. The method of claim 4, wherein the weight ratio of whey protein concentrate to DIM is about 1:1 to 20:1.
[0222] 7. A method as described in item 4, wherein the separation step is spray drying.
[0223] 8. A method as described in item 4, wherein the separation step is freeze-drying.
[0224] 9. A method for preparing polymerized whey protein microencapsulated glutathione, the method comprising the following steps:
[0225] (a) dissolving whey protein concentrate powder at 10% w / v in water to provide an aqueous solution;
[0226] (b) heating the whey protein concentrate solution to about 70° C.-80° C. for about 15 minutes to provide a polymerized whey protein solution;
[0227] (c) adding glutathione to the polymerized whey protein solution;
[0228] (d) stirring to provide a clear homogeneous solution; and
[0229] (e) Isolation of polymerized whey protein microencapsulated glutathione.
[0230] 10. The method of item 9, wherein whey protein concentrate and glutathione are used in equal amounts by weight.
[0231] 11. The method of item 9, wherein the weight ratio of whey protein concentrate to glutathione is about 1:1 to 1:2.
[0232] 12. The method of claim 9, wherein the separation step is spray drying.
[0233] 13. A method as described in claim 9, wherein the separation step is freeze-drying.
Claims
1. A method for preparing polymerized whey protein concentrate microencapsulated 3,3'-diindolylmethane (DIM), the method comprising: The following steps are involved: (a) dissolving whey protein concentrate (WPC) powder at 10% w / v in water to provide a WPC aqueous solution; (b) heating the aqueous WPC solution to at least about 70° C. to 80° C. to provide a polymerized WPC solution; (c) adding DIM powder to the polymerized WPC solution to provide a mixture; (d) adjusting the pH of the mixture to within the range of about 6.5 to about 9.0; (e) stirring the mixture during cooling from about 80° C. to about 45° C. to provide a clear homogeneous solution to achieve microencapsulation of DIM via polymerized whey protein; and (f) Isolating the polymerized WPC-microencapsulated DIM as a solid powder by freeze drying or spray drying.
2. The method of claim 1, wherein the WPC powder and the DIM powder are used in equal amounts by weight.
3. The method of claim 1, wherein the weight ratio of the WPC powder to the DIM powder is about 1:1 to 20:
1.
4. The method of claim 1, wherein the viscosity of the WPC aqueous solution after step (a) is about 100 mPas to about 300 mPas, and wherein the viscosity of the mixture after step (e) is about 3000 mPas.
5. The method of claim 1, wherein the separating step is spray drying.
6. The method of claim 1, wherein the isolating step is freeze drying.
7. A composition comprising polymerized whey protein concentrate microencapsulated 3,3'-diindolylmethane (DIM) prepared by the method of any one of the preceding claims.
Citation Information
Patent Citations
Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
AU2014200578A1
Method for decreasing inflammation and oxidative stress in mammals
CN102036670A
Nutritional compositions comprising alpha-hydroxyisocaproic acid
CN103476275A
Nicotinic acetylcholine receptor modulators
SG154114A1
